<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62252">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02132936</url>
  </required_header>
  <id_info>
    <org_study_id>LP0053-1003</org_study_id>
    <nct_id>NCT02132936</nct_id>
  </id_info>
  <brief_title>LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris</brief_title>
  <official_title>LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to compare the efficacy of treatment with LEO 90100 at Week 4 to that of
      calcipotriol plus betamethasone dipropionate (BDP) gel at Week 8 in subjects with psoriasis
      vulgaris
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Treatment success according to the PGA</measure>
    <time_frame>4 Weeks for LEO 90100 and 8 weeks for calcipotriol BDP gel</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Psoriasis Vulgaris (Plaque Psoriasis)</condition>
  <arm_group>
    <arm_group_label>LEO 90100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LEO 90100 aerosol foam, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per can, applied once daily up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerosol foam vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Aerosol foam vehicle, 60 g per can, applied once daily for up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcipotriol BDP gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcipotriol BDP gel, containing calcipotriol (as hydrate) 50 mcg/g and betamethasone 0.5 mg/g (as dipropionate), 60 g per bottle, applied once daily up to 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gel vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Gel vehicle, 60 g per bottle, applied once daily up to 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 90100 aerosol foam</intervention_name>
    <arm_group_label>LEO 90100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerosol foam vehicle</intervention_name>
    <arm_group_label>Aerosol foam vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcipotriol BDP gel</intervention_name>
    <arm_group_label>Calcipotriol BDP gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gel vehicle</intervention_name>
    <arm_group_label>Gel vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or above

          -  Psoriasis vulgaris on the trunk and/or limbs (excluding psoriasis on the genitals and
             skin folds) involving 2-30% of the Body Surface Area (BSA)

          -  A Physician's Global Assessment of disease severity (PGA) of at least mild on trunk
             and limbs

          -  A modified Psoriasis Area Severity Index (PASI) score of at least 2 on the trunk and
             limbs.

        Exclusion Criteria:

          -  Current diagnosis of guttate, erythrodermic, exfoliative or pustular psoriasis

          -  Systemic treatment with biological therapies, whether marketed or not, with a
             possible effect on psoriasis vulgaris within the following time periods prior to
             randomisation:

               -  etanercept - within 4 weeks prior to randomisation

               -  adalimumab, infliximab - within 8 weeks prior to randomisation

               -  ustekinumab - within 16 weeks prior to randomisation

               -  other products - within 4 weeks/5 half-lives prior to randomisation (whichever
                  is longer)

          -  Systemic treatment with all other therapies with a possible effect on psoriasis
             vulgaris (e.g. corticosteroids, retinoids, methotrexate, ciclosporin and other
             immunosuppressants within 4 weeks prior to randomisation)

          -  Subjects who have received treatment with any non-marketed drug substance (i.e. a
             drug which has not yet been made available for clinical use following registration)
             within 4 weeks/5 half-lives (whichever is longer) prior to randomisation.

          -  Psoralen combined with Ultraviolet A (PUVA) therapy within 4 weeks prior to
             randomisation

          -  Ultraviolet B (UVB) therapy within 2 weeks prior to randomisation

          -  Topical anti-psoriatic treatment on the trunk and limbs (except for emollients)
             within 2 weeks prior to randomisation

          -  Topical treatment on the face, scalp and skin folds with corticosteroids, vitamin D
             analogues or prescription shampoos within 2 weeks prior to randomisation

          -  Females who are pregnant, wishing to become pregnant during the trial or are
             breastfeeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>May 6, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
    <mesh_term>Betamethasone</mesh_term>
    <mesh_term>Betamethasone sodium phosphate</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
